A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

• Status: Withdrawn
• Trial end date: 2026-02-13
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Loxo Oncology, Inc.
• Collaborator: Eli Lilly and Company
• Treatments: Pirtobrutinib

Criteria

Inclusion Criteria:

• Participants must have been diagnosed with relapsing MS

• Participants must have one of the following

1. at least 1 documented relapse within the previous year, or

2. at least 2 documented relapse within the previous 2 years, or

3. at least 1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months prior to screening.

Exclusion Criteria:

• Have had a diagnosis of primary progressive MS

• Have a history of another clinically significant neurological disease

• Had a relapse of MS within 30 days prior to randomization.